nCounter® Autoimmune Profiling Panel
Helping Your Research
Get insights into immune system dysfunction quickly with our comprehensive 770 gene multiplex panel for human or mouse to evaluate the pathways, processes, and cell types involved in autoimmune disease, chronic inflammatory disease, and immunotherapy-related adverse events. Analyze autoimmune biomarkers rapidly without the need for qPCR or NGS.
- Therapeutic mechanism of action (MOA) studies
- Immunotherapy-induced adverse event investigations
- Discovery/validation of disease and therapeutic specific biomarkers
- Development of predictive signatures of drug response
- Compatible with challenging sample types such as PBMCs and FFPE
How it Works
The nCounter Autoimmune Profiling panels are designed to rapidly characterize the biology behind autoimmune disease and an aberrant immune response. Each human and mouse panel allow for a comprehensive evaluation of pathways, processes, and cell types that are involved in autoimmune disease and chronic inflammatory disorders.
Comprehensive assessment of 35 pathways and processes associated with autoimmune disease and chronic inflammatory disorders
Unique cell typing analysis feature measures the relative abundance of 14 different immune cell types
Customizable with Panel Plus option – add up to 55 genes of your choice
Streamlined workflow with just 15 minutes total hands-on time
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
The TruCulture-NanoString Solution for Immune Profiling
Recent publications (1,2) from the Milieu Interieur project at Institut Pasteur have shown the utility of the Myriad RBM TruCulture(1) whole blood collection and culture system paired with nCounter gene expression analysis.
For more information on the combined TruCulture-NanoString workflow, visit the Myriad TruCulture site.
In the Lab
The 35 pathways and processes in this panel provide a comprehensive view into immune system dysfunction in autoimmune disease and treatment-induced adverse immune events.
The Autoimmune Profiling Panels include unique cell profiling signatures to measure the relative abundance of 14 different immune cell types1. The table below summarizes each cell type represented by gene content in the panel, as qualified through biostatistical approaches and selected literature in the field of immunology.
The Autoimmune Profiling Panel is designed to encompass adaptive and innate immune system dysfunction associated with six of the most common and debilitating autoimmune diseases. The table below describes the six conditions that were emphasized in creating this panel, along with induced adverse immune events associated with immunotherapy. While this panel was designed around these six diseases, it will provide powerful immune system information for the research of any autoimmune or chronic inflammatory disorder.
Content in the Autoimmune Profiling Panel includes targets for more than 30 approved and investigational therapies for autoimmune disease and chronic inflammatory disorders.
Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylurea.
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitor has been reported to have kidney-protective benefits. To elucidate how antidiabetic agents prevent diabetic kidney disease progression, it is important to investigate their effect on the kidney environment in type 2 diabetes mellitus (DM) patients.
Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives.
Systemic autoinflammatory diseases are a heterogeneous family of disorders characterized by a dysregulation of the innate immune system, in which sterile inflammation primarily develops through antigen-independent hyperactivation of immune pathways. In most cases, they have a strong genetic background, with mutations in single genes involved in inflammation.
Synthetic hookworm-derived peptides are potent modulators of primary human immune cell function that protect against experimental colitis in vivo.
The prevalence of autoimmune diseases is on the rise globally. Currently, autoimmunity presents in over 100 different forms and affects around 9% of the world’s population.